TuHURA Biosciences filings document regulatory disclosures for a Nasdaq-listed clinical-stage immuno-oncology company. Recent 8-K reports cover operating and financial results, corporate updates on IFx-2.0, TBS-2025 and early-stage ADC programs, and material agreements tied to development funding and general corporate purposes.
The filing record also includes capital-structure disclosures for common stock, warrants, shelf and resale registration matters, secured borrowing arrangements, governance matters and Nasdaq continued-listing compliance. These documents describe the company's registered common stock, financing instruments, material-event reporting and formal updates on its cancer-immunotherapy development programs.
TuHURA Biosciences, Inc. reported a net loss of $7.5 million for the three months ended March 31, 2026, compared with $6.7 million a year earlier, as it continued to invest in its cancer immunotherapy pipeline.
Research and development expenses rose to $5.2 million, driven by IFx‑2.0 Phase 3 work, TBS‑2025 development and higher headcount, while general and administrative costs were $2.3 million. The company had $6.3 million in cash and cash equivalents and used $4.4 million in operating cash during the quarter.
TuHURA closed earlier equity financings and established a $50 million revolving credit facility with Parkview Holdings One LLC, plus a $50 million at‑the‑market equity program. Management states that existing capital resources and expected credit facility access should fund planned operations into the end of 2028 as it advances IFx‑2.0 and TBS‑2025 through clinical development.
TuHURA Biosciences, Inc. reported first quarter 2026 results and a corporate update centered on strengthening its balance sheet and advancing its oncology pipeline. The company highlighted a new $50 million non‑equity credit facility and recent regulatory and leadership developments.
The credit facility, signed with its largest stockholder, can be drawn as needed to fund operations, carries a 12% annual interest rate on drawn amounts, and matures on April 21, 2031, extending TuHURA’s anticipated cash runway into 2028. Cash and cash equivalents were $6.3 million as of March 31, 2026, and common shares outstanding were about 63.6 million.
For the quarter, research and development expenses were $5.2 million versus $4.6 million a year earlier, and general and administrative expenses were $2.3 million versus $2.0 million. Net cash outflows from operating activities were $4.4 million, while financing activities provided $7.2 million.
TuHURA received FDA Orphan Drug Designation for IFx‑2.0 in cutaneous melanoma and outlined multiple anticipated milestones across IFx‑2.0, its VISTA inhibitor TBS‑2025, and its bi‑specific ADC program, including a Phase 3 trial in Merkel Cell Carcinoma and a planned Phase 1b/2 trial in mutNPM1 relapsed/refractory AML.
TuHURA Biosciences, Inc. filed an amended report to update and correct its previously issued unaudited pro forma financial statements reflecting the June 30, 2025 acquisition of Kineta, Inc. The revised pro forma statement of operations for the year ended December 31, 2025 shows a combined net loss of $34.6 million, or $0.66 per share, based on 52.7 million weighted-average shares outstanding.
The filing describes the Kineta acquisition as a business combination with total estimated consideration of $16.6 million, including cash and TuHURA common stock, and recognition of in-process R&D and goodwill. It also details a June 2025 private placement of 4,759,309 common shares and an equal number of warrants that raised about $11.5 million in net proceeds.
TuHURA Biosciences, Inc. filed an amended annual report for 2025 to add Part III governance disclosures and correct its MD&A, while keeping its audited financial statements unchanged. The company is a clinical-stage immuno-oncology developer focused on its IFx-2.0 platform and TBS-2025 antibody.
For the year ended December 31, 2025, TuHURA reported a net loss of $30.1 million, wider than the $21.7 million loss in 2024, driven by higher research and development spending of $20.5 million and acquisition-related costs tied to the Kineta merger. General and administrative expenses rose to $7.6 million as the company scaled public-company operations.
As of December 31, 2025, TuHURA held $3.6 million in cash and cash equivalents and had an accumulated deficit of $141.2 million. During 2025 it raised capital through a June private placement of 4,759,309 shares with accompanying warrants and a December registered direct offering of 9,462,423 shares plus Series A and Series B warrants, and it completed the acquisition of Kineta in stock, issuing approximately 2.9 million shares at closing and 1.1 million additional holdback shares later in the year.
TuHURA Biosciences, Inc. entered into a Loan Agreement with Parkview Holdings One LLC, an affiliate of its largest stockholder, establishing a $50 million revolving credit facility maturing on April 21, 2031. The facility bears 12% annual interest, rising by an additional 6% during events of default, and is secured by substantially all assets of the company and its subsidiaries.
TuHURA may draw once per month, up to the greater of $1.7 million or the agreed budgeted monthly expenses, with unused capacity rolling forward. Subject to stockholder approval of related share issuances, the company expects this facility to fund operations and development programs into the first quarter of 2028. In connection with the loan, Parkview receives a low to mid‑single digit royalty on annual Net Sales of IFx‑2.0‑based products up to $450 million per year, and the agreement imposes customary covenants and change‑of‑control conversion rights.
TuHURA Biosciences filed a prospectus supplement to sell up to $50,000,000 of its common stock through an at-the-market (ATM) offering under a Sales Agreement with H.C. Wainwright & Co., LLC. The Sales Agent will receive a 3.0% commission on gross sales. The company states proceeds are intended for working capital and general corporate purposes. The prospectus uses an assumed price of $1.79 per share (last reported sale on March 31, 2026) for illustrative dilution calculations and reports 59,336,104 shares outstanding as of December 31, 2025.
TuHURA Biosciences, Inc. reported 2025 executive compensation decisions and released detailed pro forma results reflecting its acquisition of Kineta, Inc. and a June 2025 private placement. The compensation committee approved 2025 performance bonuses of $490,536 for CEO Dr. James Bianco and $163,393 for CFO Dan Dearborn, along with 5% cost-of-living raises, bringing their annual base salaries to $605,956 and $403,676, respectively.
The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2025 shows a pro forma net loss attributable to common stockholders of $34,571,619, or $0.64 per share, based on 54,277,032 weighted-average shares. It incorporates TuHURA’s acquisition of Kineta, which was valued at total consideration of $16,560,163 and treated TuHURA as the accounting acquirer, and includes a June 2025 private placement of 4,759,309 shares at a combined $2.65 per share and accompanying warrant, with matching warrants exercisable at $3.3125 per share.
TuHURA Biosciences reported fourth quarter and full year 2025 results and highlighted progress across its immuno-oncology pipeline. The company is running a Phase 3 accelerated approval trial of IFx-2.0 in advanced or metastatic Merkel Cell Carcinoma and a Phase 1b/2a study in MCC of unknown primary, while advancing VISTA inhibitor TBS-2025 and an ADC program toward key 2026–2027 milestones.
Cash and cash equivalents were $3.6 million at December 31, 2025, with an additional $7.5 million received in Q1 2026 from a 2025 registered direct offering. Research and development expenses rose to $20.5 million in 2025 from $13.3 million in 2024, and general and administrative expenses increased to $7.6 million from $3.9 million, reflecting expanded operations and the Kineta acquisition. Net cash outflows from operating activities were $27.7 million in 2025, partly offset by $19.9 million of net cash inflows from financing activities. TuHURA reported approximately 52.9 million shares outstanding as of December 31, 2025.
TuHURA Biosciences, Inc. files its annual report describing a late‑stage immuno‑oncology pipeline focused on overcoming primary and acquired resistance to cancer immunotherapies. The company is a Phase 3 clinical-stage developer centered on its IFx innate immune agonist platform.
Lead candidate IFx‑2.0 is in a single randomized, placebo‑controlled Phase 3 trial as adjunctive therapy to Keytruda in first‑line advanced or metastatic Merkel cell carcinoma under an FDA Special Protocol Assessment and accelerated approval pathway. TuHURA also acquired Kineta and its VISTA‑inhibiting antibody TBS‑2025 for planned Phase 1b/2 studies in relapsed/refractory mutNPM1 acute myeloid leukemia, and is advancing Delta Opioid Receptor–targeted bi‑functional, bi‑specific ADCs against myeloid‑derived suppressor cells.
The report outlines the company’s history of reverse mergers, licensing deals with Moffitt Cancer Center and West Virginia University for DOR technology, a broad patent estate extending into the 2040s, and an organization of 22 employees based primarily in Tampa, Florida.
Tendler Craig reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.